Huvepharma’s new fermentation plant in southern Bulgaria is now open.
The new plant has a total fermentation capacity of 3500 cubic meters, including 21 process fermenters of 160 cubic meters each and seven 20 cubic meter culture and interim fermenters. This increases Huvepharma’s total production capacity by 30%. Huvepharma now has flexibility to ferment its entire current product portfolio in one place, with additional capacity remaining to introduce new products to their range in the future.
Facilities at the new plant also include:
- Workshops for processing, drying and product formulation
- State-of-the-art warehouse facilities
- A complete power station including high-voltage substation and the respective voltage-reduction facilities
- Steam and compressed air production
- Process and cooling water production and supply
- Water and exhaust air treatment facilities
- Underground and surface infrastructure
Benefiting from the very latest production equipment and technologies, the state-of-the-art plant implements only the best practices and techniques to produce the high-quality, internationally renowned Huvepharma product portfolio.
At the new plant, the main part of the production process is automated using systems from Emerson who have been providing automation in Huvepharma factories for over 15 years. Other components of the factory come from companies including Siemens, Schneider, Cameron USA and SPX US. The fermenters were manufactured by two Bulgarian companies.
Completion of the new plant means that over 150 new jobs have been created in Peshtera. Huvepharma has hired highly qualified specialists in the fields of engineering, biology and biochemistry to work in the new facility.
“The increased capacity in our new production facility in Peshtera allows us to meet our ambitious and continuous growth plans to expand our market share in the field of fermented products including coccidiostats, antibiotics, enzymes, probiotics and human health APIs (active pharmaceutical ingredients),” stated Mr. Eddy Piron, Managing Director of Huvepharma NV.
“We have invested EUR150 million in our European production facilities despite fierce competition from other production sites around the world,” continued Mr. Piron. “Bulgaria is a member of the EU 28 and all our plants have been approved by the European regulatory authorities. We operate under European GMP (Good Manufacturing Practice) guidelines and have FDA (Food and Drug Administration) approval, making us an attractive and internationally competitive production partner.”
Mr. Piron concluded, “We are delighted to open this new facility today and look forward to sharing our world-class product range with our ever-expanding international customer base.”
